๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Role of MHC class-i antigens and the CD3 complex in the lysis of autologous human tumours by T-cell clones

โœ Scribed by T. E. Roberts; U. Shipton; M. Moore


Publisher
John Wiley and Sons
Year
1987
Tongue
French
Weight
719 KB
Volume
39
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

โœฆ Synopsis


Peripheral blood lymphocytes (PBL) of 4 patients with malignant effusions were stimulated for 6 days with purified autologous tumour cells, before isolation of the lymphoblasts and cloning by limiting dilution in interleukin-2 (IL-2). Forty-five clones were analyzed for cytotoxicity (CTX) against autologous, allogeneic tumour and erythromyeloid K562 cells of known status with respect to expression of major histocompatibility complex (MHC) antigens, estimated by reaction with the W6/32 (anti HLA, -A, -B, -C monomorphic) and TDR 31.1 (anti HLA-DR) monoclonal antibodies (MAb). All 45 clones were CD3+. Twenty-five (56%) of them were cytotoxic for at least one target; 24 were autoreactive (restricted in 7); 17 were alloreactive; 16 were K562 reactive. Under comparable conditions autoreactivity was partially blocked by W6/32 in 12/20 effector:target combinations; alloreactivity in 8/13 and K562 reactivity in 0/14. Modulation of effector cell surface CD3 antigens by OKT3 monitored by flow cytometry reduced autoreactivity in 9/14 combinations, alloreactivity in 2/6 and K562 reactivity in 0/4. W6/32 blocking and T3 modulation of cytotoxicity were almost invariably concordant against the same target. The data suggest that, to accomplish lysis of autologous and allogeneic tumour targets, certain clones require MHC recognition and a functional CD3 complex, while for others with similar target cell repertoires, there is no such requirement. It is possible that T-cell clones responding to a tumour-associated antigen (TAA) in the context of self MHC antigens can also respond to an allogeneic class-I product in the absence of TAA, and/or that aberrant class-I antigen expression on autologous tumours accounts for the alloreactivity.


๐Ÿ“œ SIMILAR VOLUMES


Regulatory role of the CD8 antigen in bo
โœ Gijs A. Van Seventer; Rene A. W. Van Lier; Karel C. Kuijpers; Hergen Spits; Corn ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 692 KB

## Regulatory role of the CD8 antigen in both CD3 and CD2 monoclonal antibody -induced nonspecific cytotoxicity of class I-and class II-allospecific cytotoxic T cell clones* We investigated the function of the CD8 moiety in antigen-specific and alternative activation of HLA class I-and HLA class I

The level of expression of class-I MHC a
โœ Roger J. A. Grand; Martin Rowe; Philip J. Byrd; Phillip H. Gallimore ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 994 KB

The level of expression of the class-I major histocompatibil-19 and 54kDa. The El region encompasses those viral genes ity (MHC) antigen was determined in a series of human em-expressed first following lytic infection and is also that area bryo cell lines transformed with either adenovirus I2 (Ad 12

The MHC class-II and CD44 molecules are
โœ Marek Zembala; Maciej Siedlar; Irena Ruggiero; Jerzy Wieckiewicz; Bozena Mytar; ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 801 KB

## Abstract Tumour necrosis factor alpha (TNF) mRNA is detected in the macrophage infiltrate surrounding the tumour, but the cellular/ molecular interactions leading to TNF gene expression in macrophages are unknown. The __in vitro__ system in which human blood monocytes are stimulated with human c

Regulation of CTL responses to MHC-restr
โœ Murrium Ahmad; Robert C. Rees; Stephanie E. McArdle; Geng Li; Shahid Mian; Clair ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 376 KB

## Abstract Direct intratumour injection of the disabled infectious singleโ€cycleโ€“herpes simplex virusโ€“encoding murine granulocyte/macrophage colonyโ€stimulating factor (DISCโ€HSVโ€“mGMโ€CSF) into established colon carcinoma CT26 tumours induced complete tumour rejection in up to 70% of treated animals (